This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
New Immuno-Oncology Solutions (NIOS): Aligning Stakeholders in the Biotech Industry
Vroom, Govert; Maribel Berges; Sastre Boquet, IsaacCase SM-1701-EEntrepreneurship, Innovation and Change, StrategyThis case focuses on a small biotech company (NIOS), located in Barcelona, Spain, that is developing a new immune-oncology product for treating pancreatic cancer. The drug that the company is developing has recently finished Phase I of clinical trials successfully and is now preparing for Phase II and III. At this point, the CEO is approached by her former PhD director, a university professor, who asks if the company is interested in licensing a ...Starting at €8.20
-
Impact America Fund: Challenges of New Fund Formation
Krauel, Patel, H; Ewald, C; Foroughi, JCase SGSB-SI139-EBusiness Ethics and Corporate Social Responsibility, Innovation and ChangeIn July 2013, Kesha Cash transitioned out of her stable role as co-founder of and fund manager for Jalia Ventures (“Jalia”), an initiative investing in early-stage mission driven “businesses operated by entrepreneurs of color,” to launch her own impact venture fund focused on underserved communities. Because Jalia had been funded and supported by Serious Change, L.P., a global impact investment fund, Cash was new to the process of fund formation...Starting at €8.20
-
New Immuno-Oncology Solutions (NIOS) - Teaching Note: Aligning stakeholders in the biotech industry
Vroom, Govert; Maribel Berges; Sastre Boquet, IsaacTeaching Note SMT-136-EEntrepreneurship, Innovation and Change, StrategyThis case focuses on a small biotech company (NIOS), located in Barcelona, Spain, that is developing a new immune-oncology product for treating pancreatic cancer. The drug that the company is developing has recently finished Phase I of clinical trials successfully and is now preparing for Phase II and III. At this point, the CEO is approached by her former PhD director, a university professor, who asks if the company is interested in licensing a ...Starting at €0.00